Generic Moxeza Availability
Last updated on Sep 11, 2024.
Moxeza is a brand name of moxifloxacin ophthalmic, approved by the FDA in the following formulation(s):
MOXEZA (moxifloxacin hydrochloride - solution/drops;ophthalmic)
-
Manufacturer: HARROW EYE
Approval date: November 19, 2010
Strength(s): EQ 0.5% BASE (discontinued) [RLD]
All of the above formulations have been discontinued.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Moxeza. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Pharmaceutical compositions containing a fluoroquinolone antibiotic drug
Patent 8,450,311
Issued: May 28, 2013
Inventor(s): Campins Inmaculada & Jiménez Nuria & Vidal Roman & Carreras Nuria & Martinez Carmen & Galán Francisco Javier
Assignee(s): Novartis AGPharmaceutical compositions containing a fluoroquinolone antibiotic drug are disclosed. The compositions exhibit improved homogeneity, improved bioavailability, lower turbidity or a combination thereof. The composition can be use as otic or nasal compositions, but are particularly useful as ophthalmic compositions.
Patent expiration dates:
- May 29, 2029✓
- May 29, 2029
-
Pharmaceutical compositions containing a fluoroquinolone antibiotic drug
Patent 9,114,168
Issued: August 25, 2015
Inventor(s): Campins Inmaculada & Jiménez Nuria & Vidal Roman & Carreras Nuria & Martinez Carmen & Galàn Francisco Javier
Assignee(s): Alcon Pharmacueticals Ltd.Pharmaceutical compositions containing a fluoroquinolone antibiotic drug are disclosed. The compositions exhibit improved homogeneity, improved bioavailability, lower turbidity or a combination thereof. The composition can be use as otic or nasal compositions, but are particularly useful as ophthalmic compositions.
Patent expiration dates:
- May 29, 2029✓
- May 29, 2029
More about Moxeza (moxifloxacin ophthalmic)
- Moxeza consumer information
- Compare alternatives
- Reviews (2)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: ophthalmic anti-infectives
- Breastfeeding
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.